GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (HKSE:09939) » Definitions » Price-to-Free-Cash-Flow

Kintor Pharmaceutical (HKSE:09939) Price-to-Free-Cash-Flow : N/A (As of Sep. 21, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Price-to-Free-Cash-Flow?

As of today (2024-09-21), Kintor Pharmaceutical's share price is HK$0.92. Kintor Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.73. Hence, Kintor Pharmaceutical's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Kintor Pharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:

HKSE:09939's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 35.86
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Kintor Pharmaceutical's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$-0.45. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was HK$-0.73.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -28.20% per year.

During the past 6 years, Kintor Pharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 18.40% per year. The lowest was -112.70% per year. And the median was -47.70% per year.


Kintor Pharmaceutical Price-to-Free-Cash-Flow Historical Data

The historical data trend for Kintor Pharmaceutical's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Price-to-Free-Cash-Flow Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kintor Pharmaceutical's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Kintor Pharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kintor Pharmaceutical's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kintor Pharmaceutical's Price-to-Free-Cash-Flow falls into.



Kintor Pharmaceutical Price-to-Free-Cash-Flow Calculation

Kintor Pharmaceutical's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.92/-0.725
=N/A

Kintor Pharmaceutical's Share Price of today is HK$0.92.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Kintor Pharmaceutical  (HKSE:09939) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Kintor Pharmaceutical Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Kintor Pharmaceutical Business Description

Traded in Other Exchanges
Address
No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-ß (GT90008), and AR-PROTAC Compound (GT20029). It operates in a single segment focusing on the research and development of medical products.
Executives
Tong Youzhi 2101 Beneficial owner
Kt International Investment Limited 2101 Beneficial owner
Guo Chuangxing 2201 Interest of corporation controlled by you
Kg Development Limited 2101 Beneficial owner
Nomura Holdings, Inc. 2201 Interest of corporation controlled by you
Tong Youzhi 2201 Interest of corporation controlled by you
Zhu Hai Ge Li Jin Rong Tou Zi Guan Li You Xian Gong Si 2101 Beneficial owner
Zhu Hai Ge Li Ji Tuan You Xian Gong Si 2201 Interest of corporation controlled by you
Sovereign Fiduciaries (hong Kong) Limited
Kiya Company Limited
Lian Xiang Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Nan Ming You Xian Gong Si 2201 Interest of corporation controlled by you
Shi Xian You Xian Gong Si 2101 Beneficial owner

Kintor Pharmaceutical Headlines

No Headlines